기본 정보
- CAS
1304-85-4- 표준 SMILES
O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-2].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-]- InChIKey
QGWDKKHSDXWPET-UHFFFAOYSA-E- 분자식
- Bi5H9N4O22
- 평균 분자량
- 1,461.99 g/mol
- 단동위원소 질량
- 1,461.87284
개요
Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
이름 및 식별자
- 우선 이름
- Bismuth Subnitrate
- IUPAC
- pentabismuth;oxygen(2-);nonahydroxide;tetranitrate
- 현지명
- 히드록시 비스무트 질산
- 영어명
- Bismuth subnitrate
- 분자식
- Bi5H9N4O22
- 분자량
- 1461.99
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
1304-85-4、54392-33-5- PubChem CID
- 73415757
- DTXSID
DTXSID40893872- ChEMBL
CHEMBL3833348- UNII
- H19J064BA5
- EC Number
- 215-136-8、611-133-4
물성
구조 계산 물성
- 극성 표면적
- 262 Ų
- 수소 결합 공여자 수
- 9
- 수소 결합 수용자 수
- 22
- 회전 가능 결합 수
- 0
- 무거운 원자 수
- 31
- 형식 전하
- 0
- 복잡도
- 18.8
실험 및 물리화학적 성질
Color/Form
HEAVY, MICROCRYSTALLINE POWDER
WHITE POWDER
Solubility
Insoluble
PRACTICALLY INSOL IN WATER, ALC; SOL IN DILUTE HYDROCHLORIC ACID & NITRIC ACID
PRACTICALLY INSOL IN ORGANIC SOLVENTS
Boiling Point
Decomposes at 260
BOILING POINT: 260 °C -HNO3 /BIONO3.H2O/
Melting Point
Decomposes at 260
260 °C DECOMP
물리화학적 성질
- 녹는점
- 260 °C · 260°C
- 밀도
- 4.928 · 4.928
- 증기압
- 0 Pa · 0Pa at 20℃
- 저장 조건
- 5 °C · Store at +5°C to +30°C.
- 용해도
- 물과 에탄올(96%)에 거의 녹지 않습니다. 분해되면서 무기산에 용해됩니다.
- 물리적 상태
- 분말/고체
- 색상
- 하얀색
- 수소이온지수(pH)
- 3.2 · 3.2 (50g/l, H2O, 20℃)(slurry)
- 수용성
- 3 · 물과 알코올에 거의 녹지 않습니다. 묽은 HNO{3} 및 HCl에 용해됨
- Merck
- 14 · 14,1284
- 안정성
- 안정성 강산화제 - 가연성 물질과 접촉하면 화재가 발생할 수 있습니다. 환원제, 유기 물질과 호환되지 않습니다.
- 주요 응용
- 의약품(소분자)
- 화장품 원료 기능
- 불투명화흡착제
- InChI
- 1S/5Bi.4NO3.9H2O.O/c;;;;;4*2-1(3)4;;;;;;;;;;/h;;;;;;;;;9*1H2;/q+1;4*+3;4*-1;;;;;;;;;;/p-9
- InChIKey
- OAVDTZZNYFIIGB-UHFFFAOYSA-E
- SMILES
- O[Bi]=O.O[Bi](O)O[N+]([O-])=O.O[Bi](O)O[N+]([O-])=O.O[Bi](O)O[N+]([O-])=O.O[Bi](O)O[N+]([O-])=O
- EPA
- Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O) (1304-85-4)
화학적 성질
White, heavy, Slightly hygroscopic powder
안전 및 규제
GHS 분류
GHS Classification
This chemical does not meet GHS hazard criteria for 58.1% (115 of 198) of all reports.
Danger
H272 (24.2%): May intensify fire; oxidizer [Danger Oxidizing liquids; Oxidizing solids]
P210, P220, P260, P261, P264, P264+P265, P270, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P370+P378, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 198 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
유해성 정보
Regulatory Information
Chemical: Bismuth hydroxide nitrate oxide, (Bi5(OH)9(NO3)4O)
Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)
REACH registered substance: Bismuth hydroxide nitrate oxide (EC: 215-136-8)
Bismuth hydroxide nitrate oxide: HSNO Approval: HSR001433 Approved with controls
Hazard Classes and Categories
Ox. Sol. 2 (24.2%)
Specific target organ toxicity - Single exposure - Category 2 (central nervous system, blood)
안전 및 보호
Storage Conditions
...MATERIALS WHICH ARE TOXIC AS STORED OR WHICH CAN DECOMPOSE INTO TOXIC COMPONENTS...SHOULD BE STORED IN A COOL, WELL-VENTILATED PLACE, OUT OF THE DIRECT RAYS OF THE SUN, AWAY FROM...FIRE HAZARD...PERIODICALLY INSPECTED & MONITORED. /NITRATES/
Keep well closed and protect from light.
독성 정보
Human Toxicity Excerpts
ESPECIALLY IN INFANTS, THE SUBNITRATE MAY BE REDUCED BY BACTERIA WITHIN THE BOWEL, TO YIELD NITRITE, WHICH CAUSES METHEMOGLOBINEMIA AFTER ABSORPTION.
A PT POISONED BY TAKING 8 G OF BISMUTH SUBNITRATE TEMPORARILY HAD FOGGY VISION ON 2ND DAY OF POISONING.
CLIN SYMPTOMS AND LAB EXAM FINDINGS OF CASE OF POISONING (CENTRAL NERVOUS SYSTEM SYNDROME) AFTER A LONG-TERM INTAKE OF BI SUBNITRICUM (3 G/DAY, 2-3 WK) ARE REPORTED. DISCONTINUATION OF DRUG COMPLETELY IMPROVED CLIN SYMPTOMS.
ORAL ADMIN...PRODUCES POISONING THROUGH THE FORMATION OF NITRITES.
Non-Human Toxicity Excerpts
FOLLOWING SC INJECTIONS (5 G OF BISMUTH SUBNITRATE EACH DAY FOR 3 DAYS), DEGENERATIVE CHANGES & INTRANUCLEAR & INTRACYTOPLASMIC INCLUSIONS APPEARED IN RENAL PROXIMAL TUBULES OF RABBITS.
.../TREATMENT/ OF DOGS BY DAILY SC INJECTION OF BISMUTH SUBNITRATE...INDUCED IRRITATION OF EYES & LACRIMATION & RESULTED IN DEVELOPMENT OF WHITE OPACITIES IN UPPER 2/3 OF CORNEAS.
MICRONIZED HEAVY BISMUTH SUBNITRATE FED TO 99 FEMALE SPF RATS 60-70 DAYS (BI 5 G/KG/DAY), WITH 69 RATS AS CONTROLS. TEST ANIMALS BODY WT MUCH LOWER. DIFFERENCES IN LIVER & KIDNEY WT OF 2 GROUPS. TEST ANIMALS BI BLOOD & CEREBRAL LEVELS 200 & 5 TIMES HIGHER, RESPECTIVELY.
IN MICE, BI SUBNITRATE (0.4 ML/20 G OF STD SOLN, IV) WAS LETHAL WHEN DISSOLVED IN WATER, BUT NOT WHEN IN NACL SOLN. MICE ADMIN 500 MG/KG ORALLY HAD SOFTER STOOLS, AS COMPARED TO CONTROLS, AND FACIAL EDEMA.
For more Non-Human Toxicity Excerpts (Complete) data for BISMUTH SUBNITRATE (6 total), please visit the HSDB record page.
안전 데이터
- wgk
- 3
- tsca
- TSCA listed
- rtecs
- EB2977000
- ridadr
- UN 1477 5.1/PG 2
- 독성
- infant,LDLo,oral,1gm/kg (1000mg/kg),"Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 134, 1969.
- HS 번호
- 2834 29 80
- risk_code
- 8-36/37/38
- hazard_code
- O,Xi
- safety_code
- 17-26-36/37/39-36
- 포장분류
- II
- 위험 등급
- 5.1
- 기존화학 물질
- KE-03350
- F 고인화성물질
- 8
- 스토리지 클래스
- 13 - Non Combustible Solids
- 유해 물질 데이터
- 1304-85-4(Hazardous Substances Data)
화학 및 산업
약리 정보
ATC Code
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Pharmacodynamics
Bismuth subnitrate acts as an antacid that exert protective effects on the gastric mucosa. In a double-blind endoscopically controlled study, bismuth substrate was demonstrated to be effective for symptomatic relief in duodenal ulcers. In the alcohol model of mucosal injury in the rat, bismuth substrate was shown to be cytoprotective. In a randomized clinical study consisting of patients with _H. pylori_-associated duodenal ulcer, adjunctive use of colloidal bismuth subnitrate in a short treatment regimen with omeprazole and clarithromycin resulted in improved eradication rate of _H. pylori_.
Mechanism of Action
Based on the findings of a clinical investigation in patients with duodenal ulcer disease and healthy volunteers receiving oral bismuth subnitrate tablets, the protective effects of bismuth subnitrate may be secondary to endogenous mucosal prostaglandin (PGE2) production, which is one of the deficient factors observed in peptic ulcer disease. Antacid neutralizing activity of bismuth subnitrate was demonstrated to have a significant postprandial effect on gastric pH.
FDA Pharmacological Classification
BISMUTHUM SUBNITRICUM
Bismuth [CS]; Bismuth [EPC]
BISMUTH SUBNITRATE
Bismuth [CS]; Bismuth [EPC]
Absorption, Distribution and Excretion
Bismuth subnitrate may undergo minimal gastrointestinal absorption which may be potentiated with concomitant administration of sulfhydryl compounds when dissolved in citrate buffer solution. Approximately 0.2% of orally administered bismuth is absorbed systematically from the gastrointestinal tract with the peak plasma concentration typically occurring within 1 hour.
Bismuth may undergo both urinary and faecal excretion, however the exact proportion contributed by each route is still unknown.
Bismuth has been shown to accumulate preferentially in the kidneys.
No pharmacokinetic data available.
WITH DAILY ORAL ADMIN OF 0.5 G/KG BISMUTH SUBNITRATE, BLOOD BI LEVELS WERE GREATER WITH HEAVY MICRONIZED (665 UG/L) THAN WITH ORDINARY HEAVY BI SUBNITRATE (85 UG/L). KIDNEY BI LEVELS WERE 17 TIMES GREATER THAN LIVER LEVELS WHILE LITTLE BI PASSED INTO THE BRAIN.
용도 및 제조
Uses
Used to make enamel fluxes, cosmetics, antacids, and antiulceratives; [Merck Index] Used as an astringent, adsorbent, and protective; in topical lotions and ointments; [HSDB]
Enameling [Category: Hobbies]
IN PREPN OF MILK OF BISMUTH, AS ASTRINGENT, ADSORBENT, & PROTECTANT
COATING AGENT IN PREPARATIONS FOR GASTRITIS; IN BLEACHING CREAMS
Medication
Formulations/Preparations
GRADES: TECHNICAL; CP; NF.
VET: /9% BISMUTH SUBNITRATE FORMULATION/... FOR TREATMENT OF SKIN CONDITIONS SUCH AS MINOR WOUNDS, ABRASIONS, ECZEMAS & INFLAMMATION OF EXTERNAL EAR CANAL.
General Manufacturing Information
Paint and Coating Manufacturing
Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O): ACTIVE
INCOMPATIBILITIES: ALKALINE BICARBONATES, SOLUBLE IODIDES, GALLIC ACID, CALOMEL, SALICYLIC ACID, TANNIN, SULFUR.
(VET): HAS BEEN USED EXTERNALLY IN DUSTING POWDERS FOR INDOLENT, MOIST OR SUPPURATING LESIONS, & AS AN X-RAY CONTRAST MEDIUM.
응용 분야
개요Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA. Bismuth Subnitrate is a basic salt that contains the equivalent of not less than 79.0 percent of bismuth trioxide (Bi2O3),calculated on the dried basis.It is both odorless and tasteless, and is used in bleaching and freckle creams, and hair dyes. Bismuth subnitrate has been used to induce metallothionein in heart tissue and kidneys and to attenuate the toxicity of Adriamycin and cisplatin compounds, respectively.
용도Bismuth subnitrate (BiNO3) is used in the cosmetics industry and to make ceramic and enamel glazes.
공급사1 곳
관련 반응
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…